Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$173.33 USD

173.33
7,686,410

+1.80 (1.05%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $173.73 +0.40 (0.23%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (85 out of 244)

Industry: Large Cap Pharmaceuticals

Zacks News

Zacks Equity Research

Theravance JAK Inhibitor Enters Phase II for Crohn's Disease

Theravance (TBPH) doses the first patient in a phase II Crohn's disease study on JAK inhibitor, TD-1473.

Zacks Equity Research

Mylan Recalls Valsartan Lots, Gets FDA Warning for Facility

Mylan (MYL) recalls batches of blood pressure medicine in the United States. The company receives warning letter from the FDA for the manufacturing facility in Morgantown, WV.

Zacks Equity Research

Shire-Takeda Deal Gets Phase I Conditional European Approval

Takeda's bid to acquire Shire (SHPG) receives conditional approval from the European Commission.

Zacks Equity Research

Glaxo Seeks Label Expansion of Nucala in Pediatric Patients

Glaxo (GSK) submits sBLA to the FDA seeking label expansion of its asthma drug, Nucala, in pediatric patients in the United States.

Zacks Equity Research

Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know

Johnson & Johnson (JNJ) closed at $147.82 in the latest trading session, marking a +1.25% move from the prior day.

Zacks Equity Research

J&J Gets Positive CHMP Opinion for Prostate Cancer Treatment

Johnson & Johnson's (J&J) apalutamide gets positive CHMP opinion for the treatment of adult patients with non-metastatic castration-resistant prostate cancer.

David Borun headshot

Stocks Stage a Late Rally to Take Some of the Sting Out of a Losing Week

With interest rates declining, investors turn their focus to Brexit and China trade negotiations

Zacks Equity Research

Johnson & Johnson (JNJ) Up 3.4% Since Last Earnings Report: Can It Continue?

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study

AbbVie's (ABBV) Mavyret demonstrates high virologic cure rates in a study evaluating it for an expanded patient population.

Zacks Equity Research

Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know

Johnson & Johnson (JNJ) closed at $145.62 in the latest trading session, marking a +0.19% move from the prior day.

Zacks Equity Research

What's in the Cards for Bayer (BAYRY) This Earnings Season?

Bayer (BAYRY) is scheduled to report third-quarter earnings on Nov 13. Acquisition of Mosanto is expected to boost sales of Crop Science segment significantly.

Zacks Equity Research

Healthcare ETF (JHMH) Hits New 52-Week High

This healthcare ETF hits a new 52-week high. Are more gains in store for this ETF?

Zacks Equity Research

Theravance (TBPH) Beats on Q3 Earnings, Inks Deal for Vibativ

Theravance Biopharma (TBPH) incurs narrower-than-expected loss in Q3. The top line betters estimates.

Zacks Equity Research

AstraZeneca's (AZN) Q3 Earnings Beat, New Drugs Drive Sales

AstraZeneca (AZN) beats earnings and sales estimates in the third quarter and maintains previously issued outlook for 2018. AstraZeneca's newer medicines sales rise 86% in the quarter.

Zacks Equity Research

Perrigo (PRGO) Beats on Q3 Earnings, Cuts View, Shares Down

Perrigo (PRGO) reports mixed third-quarter 2018 results and lowers revenue and adjusted earnings guidance for 2018 for the second straight quarter.

Zacks Equity Research

The Zacks Analyst Blog Highlights: HCA Healthcare, Molina Healthcare, Johnson & Johnson, Lockheed Martin and Boeing

The Zacks Analyst Blog Highlights: HCA Healthcare, Molina Healthcare, Johnson & Johnson, Lockheed Martin and Boeing

Swarup Gupta headshot

Democrats Hold Edge in House Battle: 5 Great Picks (Revised)

Drug and defense stocks would hugely benefit from a divided Congress.

Zacks Equity Research

Bristol-Myers, Infinity to Test Opdivo Combo for Bladder Cancer

Bristol-Myers (BMY) signs a contract with Infinity Pharmaceuticals to evaluate the combination of its Pd-1 inhibitor Opdivo and Infinity's IPI-549 for treating advanced urothelial cancer

Zacks Equity Research

The Zacks Analyst Blog Highlights: HCA Healthcare, Molina Healthcare, Johnson & Johnson, Facebook and Twitter

The Zacks Analyst Blog Highlights: HCA Healthcare, Molina Healthcare, Johnson & Johnson, Facebook and Twitter

Tirthankar Chakraborty headshot

5 Top Stocks to Make the Most of a Divided Congress

Gridlock in Washington bodes well for healthcare and defense stocks, which calls for investing in such a space for the time being.

Zacks Equity Research

Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know

Johnson & Johnson (JNJ) closed at $142.55 in the latest trading session, marking a +0.25% move from the prior day.

Sweta Killa headshot

Beaten-Down Pharma ETFs to Buy Post Q3 Results

Despite strong results, the broad market sell-off took the sheen from the pharma ETFs over the past month. These funds have a Zacks ETF Rank #2 (Buy), suggesting solid entry point on beaten down prices.

Tirthankar Chakraborty headshot

Election Day 2018: Here Are the Winners & Losers

One of the most awaited midterm elections in American history is upon us. Let's thus look at the sectors most likely to be impacted by the election results.

Swarup Gupta headshot

Democrats Hold Edge in House Battle: 5 Great Picks

Drug and defense stocks would hugely benefit from a divided Congress.

Zacks Equity Research

Pacira (PCRX) Q3 Earnings and Revenues Surpass Estimates

Pacira Pharmaceuticals (PCRX) encourages with better-than-expected earnings and revenues in Q3